About Dynavax Technologies Corporation
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California. Address: 2100 Powell Street, EmeryVille, CA, United States, 94608
Dynavax Technologies Corporation News and around…
Latest news about Dynavax Technologies Corporation (DVAX) common stock and company :
Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that it has granted nonstatutory stock options to purchase an aggregate of 115,000 shares of Dynavax common stock as inducements to 1 newly-hired employee in connection with commencement of employment with the Company.
These COVID-19 vaccine developers are all moving in response to strong late-stage results for Valneva's VLA2001.
Investors in Dynavax Technologies Corp (DVAX) saw new options become available this week, for the December 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DVAX options chain for the new December 17th contracts and identified one put and one call contract of particular interest.
Valneva SE's(NASDAQ: VALN) COVID-19 vaccine elicits a robust immune response with far fewer side effects than the ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Welcome back, trader! I hope the weekend served you well because we've got pre-market stock movers to start off Monday with! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar
Gainers Valneva SE (NASDAQ: VALN) rose 34.4% to $37.69 in pre-market trading after the company disclosed positive Phase 3 results ...
Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Valneva SE reported positive topline results from the Phase 3 pivotal trial of VLA2001, their inactivated COVID-19 vaccine candidate using Dynavax's CpG 1018® adjuvant.
David Novack, President And COO at Dynavax Technologies (NASDAQ:DVAX), made a large insider sell on October 1, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Friday showed that Novack sold 17,000 shares of Dynavax Technologies at a price of $18.23. The total transaction amounted to $309,844. Following the transaction, Novack still owns 67,066 shares of Dynavax Technologies worth $1,182,373. Dynavax Technologies shares are trading
The global pharmaceutical market has experienced significant growth in recent years. As of end-2020, the total global pharmaceutical market was valued at about 1.27 trillion U.S. dollars.
Dynavax Technologies Corporation (DVAX), a biopharmaceutical company, has inked a deal with the U.S. Department of Defense (DOD) for $22 million over two and a half years to develop a recombinant plague vaccine adjuvanted with CpG 1018. Following the announcement, shares of the company rose 1.7% on Monday. As per the terms of the agreement, a Phase 2 clinical trial will be conducted by Dynavax, combining its CpG 1018 adjuvant with the DOD’s rF1V vaccine. The Phase 2 trial is likely to commence i
Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, and the U.S. Department of Defense (DOD) today announced Dynavax has executed an agreement for approximately $22 million over two and a half years to develop a recombinant plague vaccine adjuvanted with CpG 1018®. Under the agreement, Dynavax will conduct a Phase 2 clinical trial combining its CpG 1018 adjuvant with the DOD's rF1V vaccine. The Company anticipates the P
Check out these big penny stock gainers and losersLosers Spire Global, Inc.. (NYSE: SPIR) shares fell 43.3% to ...
The Dow Jones rallied more than 390 points in today's stock market and traded near its highs of the day. The Nasdaq traded higher as well.
A possible oral COVID-19 treatment is weighing on the shares of vaccine markers like Dynavax today.
The Dow Jones led the upside in today's stock market while the Nasdaq composite reversed higher after trading in the negative.
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco Dynamic Market ETF (PWC), we found that the implied analyst target price for the ETF based upon its underlying holdings is $133.15 per unit.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...
Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that it will participate in the following investor conferences.
The Dow Jones Industrial Average traded higher in today's stock market while the Nasdaq composite diverged and traded lower on Monday.
There’s a potential new addition to the lineup of successful Covid-19 vaccines. In fact, Cowen's Phil Nadeau thinks Clover and Dynavax’ (DVAX) collaborative effort SCB-2019 appears “better tolerated than approved COVID vaccines.” Nadeau’s exuberant take follows Clover’s last Wednesday's announcement. The company disclosed that its Covid-19 vaccine SCB-2019 – which makes use of Dynavax’ adjuvant technology – showed excellent results in a Phase 3 study. The vaccine produced 100% protection against
It's definitely not a showstopper for the biotech or its CpG 1018 adjuvant.
On CNBC's "Mad Money Lightning Round," Jim Cramer said Dynavax Technologies Corporation (NASDAQ: DVAX) is good. He loves ...
During Thursday's Mad Money Lightning Round segment host Jim Cramer fielded questions about stocks from various callers. In the daily bar chart of DVAX, below, we can see two base patterns that have supported the rally so far. It is hard to see what the trading volume has been doing on this chart but the On-Balance-Volume (OBV) line has moved in a positive direction and confirms and supports the price gains this year.
Dynavax (DVAX) stock gains as partner Clover announces strong efficacy of its COVID-19 vaccine candidate against the Delta variant in pivotal study data readout.
Gainers Marin Software Incorporated (NASDAQ: MRIN) shares jumped 61.9% to close at $9.21 on Wednesday following an announcement ...
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Dynavax Technologies Corp (DVAX), where a total volume of 37,054 contracts has been traded thus far today, a contract volume which is representative of approximately 3.7 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 53% of DVAX's average daily trading volume over the past month, of 7.0 million shares..
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Today, some impressive vaccine-related news has sent Dynavax and shares of DVAX stock significantly higher as investors pile in. The post DVAX Stock: What Is the Covid-19 News Lifting Dynavax Today? appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar
A COVID-19 vaccine candidate that employs the company's adjuvant technology produced positive clinical trial results.